Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2025

Conditions
Asthma
Interventions
DRUG

AZD4604

Janus kinase 1 (JAK1) inhibitor

DRUG

Placebo to AZD4604

Placebo to AZD4604

Trial Locations (18)

2400

Research Site, København NV

8025

Research Site, Barcelona

22927

Research Site, Großhansdorf

39008

Research Site, Santander

60596

Research Site, Frankfurt

T2N 4Z6

Research Site, Calgary

V5Z 1M9

Research Site, Vancouver

H4A 3J1

Research Site, Montreal

G1V 4G5

Research Site, Québec

07010

Research Site, Palma de Mallorca

B9 5SS

Research Site, Birmingham

G12 0YN

Research Site, Glasgow

OX3 9DU

Research Site, Headington

LE3 9QP

Research Site, Leicester

L7 8YE

Research Site, Liverpool

W12 0HS

Research Site, London

M23 9QZ

Research Site, Manchester

SO9 4XY

Research Site, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY